Supplier News: CordenPharma, Curia, Sartorius & More (incl. Niowave $75M facility)
Supplier News: CordenPharma, Curia, Sartorius & More (incl. Niowave $75M facility).
Niowave
Private
Niowave is a privately-held nuclear science and radiopharmaceutical company that operates one of the few commercial-scale facilities in the United States capable of producing medical radioisotopes used in cancer imaging and therapy. The company is investing $75M in a new radioisotope production facility to secure domestic supply of critical isotopes (including actinium-225 and copper-67) used in next-generation radiopharmaceuticals.
Company Info
Sector:Radiopharmaceuticals / Nuclear Medicine
Headquarters:Lansing, Michigan, USA
Founded:2005
Website:niowaveinc.com/
Funding Round:$75M new investment in radioisotope production facility (June 2026)
Total Funding:Undisclosed venture and government-backed funding over 20-year history
Funding & Investor Relations
IPO Outlook / Plans
None publicly disclosed; private radiopharmaceutical isotope producer with state and federal contract backing.
Upcoming Milestones & Key Dates
H2 2026 - 2027
Manufacturing
Construction and commissioning of new $75M radioisotope production facility
Late 2026
Manufacturing
Commercial production ramp of Ac-225 and Cu-67 to meet radiopharma partner demand
Clinical Development Pipeline
Actinium-225 (Ac-225) production
Target: High-purity Ac-225 isotope for pharma partnersCopper-67 (Cu-67) production
Target: High-purity Cu-67 isotope for pharma partnersAdditional medical isotopes
Target: Multiple reactor and accelerator-produced isotopesRecent News
Leadership Team
Mike Zamiara
Chief Executive Officer
Careers & Job Openings